Exelixis up 1% premarket on Cabometyx data in liver cancer [Seeking Alpha]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Seeking Alpha
Healthcare | On the Move Exelixis up 1% premarket on Cabometyx data in liver cancer Jan. 24, 2020 8:00 AM ET Exelixis, Inc. (EXEL) Douglas W. House Exelixis (NASDAQ: results CheckMate 040 BMY In treatment-naïve patients receiving cabozantinib and nivolumab (n=17) and those receiving prior treatment with Bayer's Nexavar (sorafenib) (n=19), the objective response rate (ORR) was 19% and the disease control rate (responders + stable cancer) was 75%. Median progression-free survival (PFS) was 5.4 months while median overall survival (OS) was 21.5 months. In 35 patients receiving cabozantinib, nivolumab and ipilimumab (12 treatment-naïve), including 23 with prior sorafenib therapy, ORR was 29%, DCR was 83% and median PFS was 6.8 months. Median OS had not been reached at data cutoff. No new safety signals were observed. See all stocks on the move » Now read: Forty Seven: Buy The Dip In This CD47 Pioneer Ahead Of ASCO GI » Try PREMIUM
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- 3 Reasons Growth Investors Will Love Exelixis (EXEL) [Yahoo! Finance]Yahoo! Finance
- EXEL vs. CSLLY: Which Stock Is the Better Value Option? [Yahoo! Finance]Yahoo! Finance
- 3 TSX Penny Stocks With Market Caps Over CA$30M [Yahoo! Finance]Yahoo! Finance
- Zacks.com featured highlights Amazon, Maplebear, Exelixis and Doximity [Yahoo! Finance]Yahoo! Finance
- What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now? [Yahoo! Finance]Yahoo! Finance
EXEL
Earnings
- 10/29/24 - Beat
EXEL
Sec Filings
- 11/19/24 - Form 4
- 11/19/24 - Form 4
- 11/19/24 - Form 4
- EXEL's page on the SEC website